Enalapril in RAPIDISC (wafer formulation): Pharmacokinetic evaluation of a novel, convenient formulation

International Journal of Clinical Pharmacology and Therapeutics

Volumn 38, Issue 7, 2000, Pages 327-332

  Lo, M W ^a   McCrea, J B ^a   Shadle, C R ^a   Hesney, M ^a   Chiou, R ^a   Cylc, D ^a   Yuan, A S ^a   Goldberg, M R ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Bioequivalence; Compliance; Drug formulation; Enalapril; Heart failure; Hypertension; Pharmacokinetics; Urinary excretion

Indexed keywords

DRUG METABOLITE; ENALAPRIL; ENALAPRILAT; RAPIDISC;

ADULT; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; HEART FAILURE; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; MALE; NORMAL HUMAN; PATIENT COMPLIANCE;

EID: 0033939941     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP38327     Document Type: Article

References (18)

1. Andersen O, Zweidorff OK, Hjelde T, Rodland EA 1995 Problems when swallowing tablets: a questionnaire study from general practice. Tidsskr Nor Laegeforen (Norwegian J Med) 115: 947-949
2. Beermann B, Till A, Gomez HJ, Hichens M, Bolognese JA, Junggren I-L 1989 Pharmacokinetics of lisinopril (iv/po) in healthy volunteers. Biopharm Drug Disposit 10: 397-409
3. Chow SC, Liu JP 1992 Design and Analysis of Bioavailability and Bioequivalence Studies. Marcel Dekker, New York, pp 154-161
4. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M 1991 A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325: 303-310
5. CONSENSUS Trial Study Group 1987 Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316: 1429-1435
6. Dahlof B, Pennert K, Hansson L 1992 Reversal of left ventricular hypertrophy in hypertensive patients. A meta-analysis of 109 treatment studies. Am J Hypertens 5: 95-110
7. Davis M, Pittard J 1998 Current Thinking: Enalapril (Innovace). Prescriber 2 (Suppl): 1-2
8. Dunbar-Jacob J, Dwyer K, Dunning EJ 1991 Compliance with antihypertensive regimen: a review of research in the 1980s. Ann Behav Med 13: 31-39
9. Haynes RB 1976 A critical review of the "determinants" of patient compliance with therapeutic regimens. In: Sackett DL, Haynes RB (eds) Compliance with Therapeutic Regimens. The Johns Hopkins University Press, Baltimore, pp 26-39
10. Helgeland A, Strommen R, Hagelund CH, Tretli S 1986 Enalapril, atenolol, and hydrochlorothiazide in mild to moderate hypertension. A comparative multicentre study in general practice in Norway. Lancet 1: 872-875
11. Hichens M, Hand EL, Mulcahy WS 1981 Radio-immunoassay for angiotensin-converting enzyme inhibitors. Ligand Quarterly 4: 43
12. Schnaper HW, Stein G, Schoenberger JA, Leon AS, Tuck ML, Taylor AA, Liss C, Shapiro DA 1987 Comparison of enalapril and thiazide diuretics in the elderly hypertensive patient. Gerontology 33 (Suppl I): 24-35
13. Schuirmann DJ 1987 A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 15: 657-680
14. The SOLVD Investigators 1991 Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325: 293-302
15. The SOLVD Investigators 1992 Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327: 685-691
16. Till AE, Irvin JD, Hichens M, Lee RB, Davids RO, Swanson B, Vlasses PH 1982 Pharmacodynamics and disposition of intravenous MK-422, the diacid metabolite of enalapril maleate. Clin Pharmacol Ther 31: 275
17. Ulm EH, Hichens M, Gomez HJ, Till AE, Hand E, Vassil TC, Biollaz J, Brunner HR, Schelling JL 1982 Enalapril maleate and a lysine analogue (MK-521): disposition in man. Br J Clin Pharmacol 14: 357-362
18. Ulm EH 1983 Enalapril maleate (MK-421), a potent, nonsulfhydryl angiotensin-converting enzyme inhibitor: absorption, disposition, and metabolism in man. Drug Metab Rev 14: 99-110